Skip to content

Ligand Pharmaceuticals LGND Income taxes receivable

Income taxes receivable at other companies

Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.51B+96.7%
Enterprise value$5.4B+95.4%
P/E35.9×
P/S20.1×+4.6×

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxesReceivable.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's income taxes receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's income taxes receivable?
Ligand Pharmaceuticals (LGND) reported income taxes receivable of $1.42M in Q1 2026.
How has Ligand Pharmaceuticals's income taxes receivable changed year-over-year?
Ligand Pharmaceuticals's income taxes receivable decreased by 67.4% year-over-year, from $4.34M to $1.42M.
What is the long-term trend for Ligand Pharmaceuticals's income taxes receivable?
Over 5 years (2020 to 2025), Ligand Pharmaceuticals's income taxes receivable has grown at a -8.2% compound annual growth rate (CAGR), from $2.22M to $1.45M.
What does income taxes receivable mean?
Income tax refunds or overpayments expected from tax authorities, including estimated tax prepayments in excess of actual liability.